Skip to main content
Premium Trial:

Request an Annual Quote

Bio Ventures to Oversee Alnylam, GSK IP Pool for Neglected Disease Research


Alnylam Pharmaceuticals and GlaxoSmithKline have selected non-profit Bio Ventures for Global Health to oversee the an intellectual property pool that the companies formed last year to assist with the discovery and development of new treatments for neglected tropical diseases.

"By adopting a more accessible approach to intellectual property, the pool facilitates access to compounds and technologies and, most importantly, industrial know-how for organizations that want to conduct research on treatments for these neglected diseases," the companies said.

As the pool's administrator, Bio Ventures will organize disease-specific meetings to "identify the gaps in expertise and intellectual property that currently exist in product development for neglected diseases," they added. "Bio Ventures for Global Health will then help global health researchers work with industry to fill these gaps so that the resources generously made available by companies will be used to create medicines for neglected diseases faster and more efficiently."

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.